No Data
No Data
BofA Securities Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Maintains Target Price $21
BofA Securities analyst Jason Gerberry maintains $Teva Pharmaceutical Industries(TEVA.US)$ with a buy rating, and maintains the target price at $21.According to TipRanks data, the analyst has a succes
Sector Update: Health Care Stocks Slipping in Afternoon Trading
Health care stocks were declining Monday afternoon, with the NYSE Health Care Index down 0.3% and the Health Care Select Sector SPDR Fund (XLV) shedding 0.6%. The iShares Biotechnology ETF (IBB) fell
Update: Market Chatter: Teva Pharmaceuticals Faces FTC Probe on Patent Listings
(Adds details starting in second paragraph.) Teva Pharmaceutical Industries (TEVA) faces a Federal Trade Commission investigation into the company's alleged refusal to remove two dozen patents for its
Teva Focus of FTC Investigation Over Inhaler Patents
FTC Opens Investigation Into Teva Pharmaceuticals, Washington Post Reports
09:50 AM EDT, 07/01/2024 (MT Newswires) -- FTC Opens Investigation Into Teva Pharmaceuticals, Washington Post Reports Price: 16.23, Change: -0.02, Percent Change: -0.12
Vanda Will Request Relief From Court That Includes Order Requiring Defendants to Discontinue Marketing Generic Versions of HETLIOZ >VNDA
Vanda Will Request Relief From Court That Includes Order Requiring Defendants to Discontinue Marketing Generic Versions of HETLIOZ >VNDA
loading...